223253-85-8

Upstream product

• 10200-43-8 2-methyl-4-carbethoxy-1,3-oxazole 
• 483987-66-2 2-[4-(2-isopropoxy-phenyl)-piperazin-1-ylmethyl]-oxazole-4-carboxylic acid ethyl ester 
• 142841-00-7 2-[bromomethyl]-4-oxazolecarboxylic acid ethyl ester 
• 483987-67-3 {2-[4-(2-isopropoxy-phenyl)-piperazin-1-ylmethyl]-oxazol-4-yl}-methanol 

Relevant academic research and scientific papers

Arylpiperazine substituted heterocycles as selective alpha(1a) adrenergic antagonists.

Antagonists of the alpha(1)-adrenergic receptors (alpha(1)-ARs) are useful for the treatment of benign prostatic hyperplasia. A series of potent and subtype-selective alpha(1a)-AR antagonists has been synthesized, displaying in vitro binding affinity in the low the nanomolar range.

Heterocycles useful in the treatment of benign prostatic hyperplasia

This invention relates a to a series of heterocyclic substituted piperazines of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the α-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.